Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Pharmacology

Background:

• Endocannabinoids are lipid mediators with known hypotensive and cardiodepressor effects.
• The endocannabinoid system's role in cardiovascular regulation, particularly in hypertension, requires further investigation.

Purpose of the Study:

• To investigate the role of the endocannabinoid system in regulating cardiovascular function in hypertension.
• To determine if modulating endocannabinoid activity can impact blood pressure and cardiac performance in hypertensive models.

Main Methods:

• Studies were conducted in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats.
• Treatments included cannabinoid-1 receptor (CB1) antagonists, fatty acid amidohydrolase (FAAH) inhibitors to prevent anandamide degradation, and CB1 agonists.
• Measurements included blood pressure, left ventricular contractile performance, and vascular resistance.

Main Results:

• CB1 antagonists increased blood pressure and cardiac contractility in SHR.
• Inhibiting anandamide degradation reduced blood pressure, cardiac contractility, and vascular resistance in SHR to normotensive levels.
• These effects were blocked by CB1 antagonists and were not observed in normotensive rats.
• CB1 agonists demonstrated greater hypotensive effects in SHR compared to normotensive rats.
• CB1 receptor expression was elevated in the heart and aortic endothelium of SHR.

Conclusions:

• Endocannabinoids exert a tonic suppressive effect on cardiac contractility in the hypertensive state.
• Enhancing endogenous anandamide's CB1-mediated effects through hydrolysis inhibition can normalize blood pressure.
• The endocannabinoid system presents a promising therapeutic target for managing hypertension.